Severe side effects with high-dose versus standard-dose imatinib
. | No. (%) with grades 3-4 toxicity . | . | |
|---|---|---|---|
| Toxicity . | Study group . | Historical control . | |
| Fluid retention | 1 (1) | 0 (0) | |
| Bone pain | 3 (3) | 1 (2) | |
| Skin rash | 7 (6) | 3 (6) | |
| Fatigue | 1 (1) | 1 (2) | |
| Nausea/vomiting | 1 (1) | 0 | |
| Diarrhea | 1 (1) | 0 | |
| Abnormal liver function tests | 8 (7) | 5 (10) | |
| Cardiac | 4 (4) | 1 (2) | |
| Anemia* | 11 (10) | 2 (4) | |
| Neutropenia | 41 (36) | 10 (20) | |
| Thrombocytopenia | 29 (25) | 6 (12) | |
. | No. (%) with grades 3-4 toxicity . | . | |
|---|---|---|---|
| Toxicity . | Study group . | Historical control . | |
| Fluid retention | 1 (1) | 0 (0) | |
| Bone pain | 3 (3) | 1 (2) | |
| Skin rash | 7 (6) | 3 (6) | |
| Fatigue | 1 (1) | 1 (2) | |
| Nausea/vomiting | 1 (1) | 0 | |
| Diarrhea | 1 (1) | 0 | |
| Abnormal liver function tests | 8 (7) | 5 (10) | |
| Cardiac | 4 (4) | 1 (2) | |
| Anemia* | 11 (10) | 2 (4) | |
| Neutropenia | 41 (36) | 10 (20) | |
| Thrombocytopenia | 29 (25) | 6 (12) | |
Populations are as follows: study group, N = 114; historical control, N = 50.
P values for differences were as follows: anemia, P = .35; neutropenia, P = .05; and thrombocytopenia, P = .06.